Lecanemab · Leqembi

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Alzheimer's Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: Clarity AD (NCT03887455) · Phase 3 · met primary endpoint · grade pending

track record: Partial signal

Also approved (7)
CN
  • LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for mild cognitive impairment (MCI) due to Alzheimer's diseaseeisai.com
  • Treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementiaeisai.com
Product first approved 2024
JP
  • LEQEMBI Pen, the subcutaneous formulation, for the treatment of early Alzheimer's disease (new route of administration)investors.biogen.com
  • Slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer’s diseasePMDA
Product first approved 2023
CA
  • LEQEMBI (lecanemab for injection) is indicated for: The treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early Alzheimer's disease), who are apolipoprotein E ε4 (ApoE ε4) noncarriers or heterozygotes, and who have confirmed amyloid pathology. Important instructions to ensure proper patient selection for the treatment with LEQEMBI are provided in sections 3 Serious Warnings and Precautions Box; 4.1 Dosing considerations; 7 Warnings and Precautions. An educational program has been developed for healthcare...
Product first approved 2025Health Canada
EU
  • Leqembi is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E 4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology (see section 4.4).
Product first approved 2025EMA
UK
  • Mild cognitive impairment or mild dementia due to Alzheimer's disease
Product first approved 2024alzint.org

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Alzheimer's Disease
NCT06384573 · Washington University School of Medicine
2024-06-10 – 2030-06 · Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
What this study did
Phase 2/3 (1)
Alzheimer's Disease
Phase 2 (3)
Alzheimer's Disease
NCT07212062 · Neurology Office of South Florida
2025-12-01 – 2028-12-30 · Alzheimers Disease
What this study did
NCT06602258 · Eisai Inc.
2024-09-30 – 2027-08-18 · Alzheimer's Disease
What this study did
Phase 1 (5)
Alzheimer's Disease
NCT05469009 · Ali Rezai
2022-07-14 – 2029-07 · Mild Cognitive Impairment, Alzheimer Disease 1
What this study did
NCT06992804 · Xuanwu Hospital, Beijing
2025-05-28 – 2027-01-20 · Alzheimer Disease
What this study did
Other / comorbidity
NCT05533801 · Eisai Inc.
2022-09-06 – 2023-01-06 · Healthy Volunteers
What this study did
NCT05045716 · Eisai Inc.
2021-09-07 – 2021-12-07 · Healthy Volunteers
What this study did
Phase 4 (3)
Alzheimer's Disease
NCT07688460 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2026-07-10 – 2029-03-30 · Alzheimer Disease
What this study did
NCT07604896 · First Affiliated Hospital of Wenzhou Medical University
2026-01-01 – 2028-12-31 · Alzheimer s Disease, Alzheimer Dementia (AD), MCI-AD, Early Stage Alzheimer's Disease
What this study did
NCT07034222 · Ruijin Hospital
2024-02-01 – 2026-01-01 · Alzheimer's Disease(AD)
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07544953 · Yonsei University
2026-05 – 2030-11 · Parkinson Disease
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Alzheimer's Disease
NCT06530732 · Zhejiang Provincial People's Hospital
2024-07-01 – 2026-09-30 · Alzheimer's Disease
What this study did
Phase 2/3 (1)
Alzheimer's Disease
NCT05269394 · Washington University School of Medicine
2021-12-22 – 2028-07 · Alzheimers Disease, Dementia, Alzheimers Disease, Familial
What this study did

Competitive landscape

This mechanism is crowded: 9 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Alzheimer's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lecanemab (Leqembi): this drugApprovedMonoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signal
NCT01767311: ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. missed
Benzgalantamine (Zunveyl)ApprovedSmall moleculeAcetylcholinesterase/nicotinic receptor (prodrug)not yet gradedNo reviewed efficacy summary in this indication
Donanemab (Kisunla)ApprovedMonoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signal
NCT05108922: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6)
Donepezil (Aricept)ApprovedSmall moleculeAcetylcholinesterasePartial signal
NCT00630851: Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized).
AR1001Phase 3Small moleculePDE5Partial signal
NCT03625622: Primary (ADAS-Cog-13 at Week 26): no significant differences between treatment groups in the overall population; post-hoc monotherapy subgroup on AR1001 30 mg improved 4.019 points (p=0.012). missed
BezisterimPhase 3Small moleculeERK/NF-kB inflammatoryPartial signalNo reviewed efficacy summary in this indication
Brexpiprazole (Rexulti)Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT01862640: Change in CMAI Total score from baseline to Week 12 vs placebo (Study 1 = NCT01862640): brexpiprazole 2mg/day adjusted mean difference -3.77 (95% CI -7.38 to -0.17), p=0.040; brexpiprazole 1mg/day 0.23 (95% CI -3.40 to 3.86), p=0.90
NCT03620981: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. (Baseline and 10 weeks first dose, on average 10 weeks): Brexpiprazole 1 mg -11.7 units on a scale (Standard Error 1.2) | Brexpiprazole 2 mg -15.2 units on a scale (Standard Error 1.05) vs Placebo -8 units on a scale (Standard Error 1.03)
BuntanetapPhase 3Small moleculeAPP/tau/alpha-synuclein/TDP-43 (translation)Partial signal
NCT05686044: ADAS-Cog11 change at Week 12: -2.32 placebo vs -1.34 (7.5 mg), -3.01 (15 mg), and -2.24 (30 mg) buntanetap/Posiphen; ADCS-CGIC at Week 12: 3.58 placebo vs 3.96 (7.5 mg), 3.61 (15 mg), and 3.83 (30 mg).
Hydromethylthionine MesylatePhase 3Small moleculeTau aggregation; AcetylcholinePartial signal
NCT03446001: Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control) (52 weeks): TRx0237 16 mg/Day 1.34 score on a scale (95% CI 0.32 to 2.36) vs Control 1.71 score on a scale (95% CI 0.69 to 2.73)
NCT01689233: As-randomized primary comparison (100 mg vs 4 mg twice daily, the trial's pre-specified design): no significant difference on primary or secondary outcomes. Post-hoc modified-primary-outcome monotherapy cohort analysis: ADAS-cog effect size -3.14 (95% CI -5.32 to -0.97, p=0.0047) for 100 mg monotherapy (n=76) vs 4 mg as-randomized (n=388); -4.22 (95% CI -6.19 to -2.24, p<0.0001) for 4 mg monotherapy (n=79) vs 4 mg add-on (n=309)
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01872598: Co-primary endpoints at week 24, masitinib 4.5 mg/kg/day vs placebo, each tested at 2.5%: ADAS-cog difference -2.15 (97.5% CI -3.48 to -0.81), p<0.001 (met); ADCS-ADL difference +1.82 (97.5% CI -0.15 to 3.79), p=0.038 (not met at the 2.5% level)
MasupirdinePhase 3Small moleculeSerotonin 5-HT6 receptorPartial signal
NCT02580305: ADAS-Cog 11 change from baseline at Week 26: placebo +2.6 (SE 0.5); masupirdine 50 mg +2.0 (SE 0.5), difference vs placebo -0.5 (95% CI -1.8, 0.7; P=.41); masupirdine 100 mg +2.5 (SE 0.5), difference vs placebo -0.1 (95% CI -1.4, 1.2; P=.90) missed
MLC901 (NeuroAiD II)Phase 3BotanicalTraditional Chinese medicine (multi-component)not yet gradedNo reviewed efficacy summary in this indication
RemlifanserinPhase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
RemternetugPhase 3Monoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signalNo reviewed efficacy summary in this indication
Sodium OligomannatePhase 3Small moleculeGut microbiome / neuroinflammationReliable signal
NCT02293915: Change in ADAS-cog12 from baseline to Week 36 (GV-971 minus placebo): -2.15 points (95% CI -3.07 to -1.23; p<0.0001; Cohen's d 0.53), favoring GV-971
TertomotidePhase 3PeptideTelomerase (hTERT)Partial signal
NCT05189210: 52주 차 ADAS-cog11의 최소제곱평균값 변화량은 GV1001 0.56mg과 1.12mg 투약군에서 각각 4.14점, 4.31점으로 위약군 4.30점 (LS-mean change in ADAS-cog11 at week 52: GV1001 0.56 mg 4.14 points, 1.12 mg 4.31 points, placebo 4.30 points; not statistically significant) missed
TricaprilinPhase 3Small moleculeKetone-body metabolismPartial signal
NCT01741194: Change from baseline at 26 weeks, ADAS-Cog11 (APOE4 non-carriers): placebo (n=138) 0.0 vs AC-1204/tricaprilin (n=137) 0.6; LS mean difference -0.761, p=0.2458 (not significant) missed
TrontinemabPhase 3Multispecific antibodyAmyloid-beta (monoclonal antibody)not yet gradedNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
AGB101Phase 2/3Small moleculeSynaptic vesicle glycoprotein 2A (SV2A), low-dosePartial signal
NCT03486938: CDR-SB difference vs placebo -0.10 (95% CI -0.85 to 0.58), not significant missed
BlarcamesinePhase 2/3Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT03790709: Co-primary endpoints at 48 weeks: ADAS-Cog13 difference vs placebo -2.027 (95% CI -3.522 to -0.533; P = 0.008); ADCS-ADL difference 0.775 (95% CI -0.874 to 2.423; P = 0.357, not significant). missed
DeramciclanePhase 2/3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
DeraphanPhase 2/3Small moleculeNMDA receptor / 5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Emestedastat (Xanamem)Phase 2/3Small molecule11-beta-HSD1Partial signal
NCT02727699: ADAS-Cog v14 (Baseline, Week 12): Xanamem™ -1.5 units on a scale (Standard Deviation 6.47) vs Placebo -0.7 units on a scale (Standard Deviation 6.65)
EtalanetugPhase 2/3Monoclonal antibodyTau (monoclonal antibody)Weak signalFeatured results are safety only in this race
NivegacetorPhase 2/3UndisclosedGamma-secretase (modulator)not yet gradedNo reviewed efficacy summary in this indication
PM012Phase 2/3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
T3D-959Phase 2/3Small moleculePPAR delta/gammaPartial signalNo reviewed efficacy summary in this indication
50561Phase 2Small moleculeRAC1Partial signalNo reviewed efficacy summary in this indication
AADvac1Phase 2VaccineTauWeak signalFeatured results are safety only in this race
ABvac40Phase 2VaccineAmyloid-beta (Aβx-40)Partial signalFeatured results are non-efficacy and safety only in this race
ACI-35.030Phase 2VaccineTauPartial signalFeatured results are safety only in this race
AD04Phase 2VaccineAluminium hydroxide (Alhydrogel)not yet gradedNo reviewed efficacy summary in this indication
AstroStemPhase 2Cell therapyMesenchymal stem cell therapyWeak signal
NCT03117738: ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7.
AV-1959RPhase 2VaccineAmyloid-betaWeak signalFeatured results are safety only in this race
BepranemabPhase 2Monoclonal antibodyTau (monoclonal antibody)Partial signal
NCT04867616: Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
BEY2153Phase 2Small moleculeAPP/tau (translation)Partial signalNo reviewed efficacy summary in this indication
CerebrolysinPhase 2PeptidePorcine brain-derived neuropeptide mixture (multi-target)Partial signal
NCT00911807: Week 28 ADAS-COG+ change: -2.348 Cerebrolysin + donepezil, -1.711 Cerebrolysin, and -1.246 donepezil; overall p=0.6348. Cerebrolysin + donepezil vs donepezil: mean difference -1.080 (95% CI -3.324 to 1.163; p=0.3434). missed
DeulumateperonePhase 2Small moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
DiranersenPhase 2RNA / oligonucleotideMAPT mRNA (RNAi/ASO)Weak signal
NCT05399888: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. missed
Edaravone (TTYP01)Phase 2Small moleculeoxidative stressnot yet gradedNo reviewed efficacy summary in this indication
EnrupatinibPhase 2Small moleculeCSF-1Rnot yet gradedNo reviewed efficacy summary in this indication
HT-4253Phase 2Small moleculeLRRK2not yet gradedNo reviewed efficacy summary in this indication
Laromestrocel (Lomecel-B)Phase 2Cell therapyMesenchymal stem cell therapyWeak signalFeatured results are safety only in this race
Lemborexant (Dayvigo)Phase 2Small moleculeOrexin receptor (repositioned)Partial signal
NCT03001557: 4-week actigraphy endpoints vs placebo: L5 (restlessness measure) significantly decreased at 2.5mg, 5mg and 15mg doses (all p<0.05); relative amplitude significantly improved at 5mg and 15mg (both p<0.05); mean duration of sleep bouts significantly improved at 5mg (p<0.01) and 15mg (p=0.002).
LeronlimabPhase 2Monoclonal antibodyCCR5 co-receptornot yet gradedNo reviewed efficacy summary in this indication
LHP588Phase 2Small moleculeGingipainnot yet gradedNo reviewed efficacy summary in this indication
Lifonebart (VHB937)Phase 2Monoclonal antibodyTREM2not yet gradedNo reviewed efficacy summary in this indication
MivelsiranPhase 2RNA / oligonucleotideAPP mRNA (RNAi)not yet gradedNo reviewed efficacy summary in this indication
MK-2214Phase 2Monoclonal antibodyPhospho-tau (pSer413)Partial signalFeatured results are safety only in this race
MoponetugPhase 2Monoclonal antibodyTau (monoclonal antibody)not yet gradedNo reviewed efficacy summary in this indication
NTRX-07Phase 2Small moleculeCB2 receptorWeak signalFeatured results are safety only in this race
ONO-2020Phase 2Small moleculeEpigenetic regulation (target undisclosed)not yet gradedNo reviewed efficacy summary in this indication
PegipanerminPhase 2Biologic (subtype unspecified)Soluble TNF (selective)Partial signal
NCT05318976: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) (24 Weeks): 1.0 mg/kg XPro1595 0.05 z-score (Standard Error 0.04) vs 1.0 mg/kg Placebo 0.07 z-score (Standard Error 0.05) missed
PRI-002Phase 2Small moleculeAmyloid-beta-42 oligomerizationPartial signalNo reviewed efficacy summary in this indication
RB-ADSCPhase 2Cell therapyMesenchymal stem cell therapynot yet gradedNo reviewed efficacy summary in this indication
RO7269162Phase 2Small moleculeGamma-secretasenot yet gradedNo reviewed efficacy summary in this indication
SAR448851Phase 2Small moleculeTREM2Weak signalFeatured results are safety only in this race
SeltorexantPhase 2Small moleculeOrexin-2 receptor (OX2R)not yet gradedNo reviewed efficacy summary in this indication
SHR-1707Phase 2Monoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signalNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2Small moleculeDendritic spine densitynot yet gradedNo reviewed efficacy summary in this indication
TisolagilinePhase 2Small moleculeMAO-Bnot yet gradedNo reviewed efficacy summary in this indication
TML-6Phase 2Small moleculeAutolysosome (multi-target curcumin analogue)Weak signalNo reviewed efficacy summary in this indication
TraneurocinPhase 2Small molecule—Partial signalNo reviewed efficacy summary in this indication
ABBV-1758Phase 1/2Monoclonal antibodyAmyloid-beta (monoclonal antibody)not yet gradedNo reviewed efficacy summary in this indication
ALIA-1758Phase 1Monoclonal antibodyAmyloid-beta (monoclonal antibody)Weak signalNo reviewed efficacy summary in this indication
CM383Phase 1Monoclonal antibodyAmyloid-beta (monoclonal antibody)Weak signalNo reviewed efficacy summary in this indication
PMN310Phase 1Monoclonal antibodyAmyloid-beta (monoclonal antibody)not yet gradedNo reviewed efficacy summary in this indication
SabirnetugDiscontinuedMonoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signalFeatured results are safety only in this race

Large race: only the 69 furthest-along competitors are listed; 53 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Leqembi (Lecanemab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Alzheimer's DiseaseActive not recruiting
Est. primary completion 2026-12-03 · NCT06602258 · CT.gov ↗
What to watch
Phase 3Alzheimer's DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT03887455 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
Phase 4Alzheimer's DiseaseRecruiting
Est. primary completion 2027-12-31 · NCT07604896 · CT.gov ↗
What to watch
2028 (3)
April 2028 (2)
Phase 2/3Alzheimer's DiseaseActive not recruiting
Est. primary completion 2028-04 · NCT01760005 · CT.gov ↗
What to watch
Phase 2Alzheimer's DiseaseNot yet recruiting
Est. primary completion 2028-04-01 · NCT07212062 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Alzheimer's DiseaseActive not recruiting
Est. primary completion 2028-12-21 · NCT04468659 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Phase 4Alzheimer's DiseaseRecruiting
Est. primary completion 2029-03-30 · NCT07688460 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1Alzheimer's DiseaseActive not recruiting
Est. primary completion 2029-07 · NCT05469009 · CT.gov ↗
What to watch
2030 (2)
June 2030 (2)
Phase 3Alzheimer's DiseaseActive not recruiting
Est. primary completion 2030-06 · NCT06384573 · CT.gov ↗
What to watch
Early phase / not applicableParkinson DiseaseNot yet recruiting
Est. primary completion 2030-06 · NCT07544953 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(16)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 September 2026ApprovalNMPA approves Leqembi subcutaneous formulation as initiation treatment in China
CN, NMPA · Source ↗
September 2026ApprovalJapan approves the LEQEMBI Pen subcutaneous formulation
JP, MHLW/PMDA · Eisai · Source ↗
24 August 2026FDA action dateFDA extends PDUFA date for LEQEMBI IQLIK starting dose sBLA to August 24, 2026
US, FDA · Source ↗
13 July 2026ApprovalFDA approves LEQEMBI IQLIK subcutaneous initiation dose in early Alzheimer's
US, FDA · Source ↗
24 May 2026FDA action datePDUFA action date set for LEQEMBI IQLIK starting dose
US, FDA · Source ↗
25 January 2026Filing acceptedFDA accepts sBLA for LEQEMBI IQLIK subcutaneous starting dose
US, FDA · Source ↗
25 January 2026Priority reviewPriority Review granted for LEQEMBI IQLIK starting dose sBLA
US, FDA · Source ↗
January 2026Filing acceptedChina accepts BLA for subcutaneous LEQEMBI
CN, NMPA · Source ↗
25 November 2025Filing submittedRolling sBLA submission completed for LEQEMBI IQLIK starting dose
US, FDA · Source ↗
14 November 2025ApprovalMHRA approves LEQEMBI IV maintenance dosing in the UK
UK, MHRA · Source ↗
2 September 2025Filing submittedRolling sBLA initiated for LEQEMBI IQLIK starting dose
US, FDA · Source ↗
31 August 2025FDA action datePDUFA date for LEQEMBI subcutaneous maintenance BLA
US, FDA · Source ↗

The 12 most recent of 16 past events are shown.